Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer Translating Science Into Clinical Practice

Overview

Join the Oncology Brothers together with renowned leading experts as they uncover the latest advances for NTRK fusion-positive cancers and how the recent evidence is transforming clinical practice. Don’t miss the opportunity to deepen your understanding of the optimal management of this rare cancer and how to better tailor treatment for the individual patient.

Speakers

Rahul Gosain, MD, MBA

Host

Medical Director, Wilmot Cancer Institute at Webster

Director, Wilmot Cancer Institute Regional Infusion Services

Assistant Professor of Clinical Medicine

Wilmot Cancer Institute

University of Rochester

Rochester, New York, United States

Rohit Gosain, MD

Host

Director, Roswell Park Care Network Southtowns

Assistant Professor of Clinical Medicine

Roswell Park Comprehensive Cancer Center

University of Buffalo

Buffalo, New York, United States

David S. Hong, MD

Faculty

Medical Oncologist

Professor and Deputy Chair, Department of Investigational Cancer Therapeutics

Division of Cancer Medicine

Clinical Medical Director

Clinical and Translational Research Center

University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

Theodore W. Laetsch, MD

Faculty

Pediatric Oncologist

Director, Developmental Therapeutics Program

Director, Very Rare Malignant Tumors Program

Associate Professor of Pediatrics

Children’s Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Jarushka Naidoo, MB, BCH, MHS

Faculty

Adjunct Professor of Medical Oncology

Johns Hopkins University

Baltimore, Maryland, United States

Consultant Medical Oncologist

Beaumont RCSI Cancer Centre

Dublin, Ireland

Agenda

6:15 pm

Meal and Registration

6:45 pm

Welcome and Introduction

Oncology Brothers

6:55 pm

Tumor-Agnostic Therapies for NTRK Fusion-Positive Cancers: Where Are We Today?

David S. Hong, MD

7:05 pm

Personalized Strategies for NTRK Fusion-Positive Lung Cancer

Jarushka Naidoo, MB, BCH, MHS

7:20 pm

Clinical Pearls in NTRK Fusion-Positive Pediatric Cancer Management

Theodore W. Laetsch, MD

7:35 pm

Expert Quickfire: Latest Advances in NTRK Fusion-Positive Tumors

All faculty

7:50 pm

Conversation with the Experts: Addressing Tumor-Agnostic Challenges in Clinical Practice

All faculty

8:10 pm

Q&A and Concluding Remarks

Oncology Brothers

8:15 pm

Adjourn

720 S Michigan Ave, Room: International North, Chicago, IL, 60605

Get Directions

Program Information

Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Physicians[/bold] [break] Medscape, LLC designates this live activity for a maximum of 1.5 [bold][italic]AMA PRA Category 1 Credits[/italic][/bold]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives

Upon completion of this activity, participants will:[break] [break] Have increased knowledge regarding the[list][item]Latest clinical data of tumor-agnostic treatment for [italic]NTRK[/italic] fusion-positive cancer[item]Best practice for molecular testing to detect [italic]NTRK[/italic] gene fusions[/list] Have greater competence related to [list][item]Tailoring treatment for patients with [italic]NTRK[/italic] fusion-positive lung cancer[/list] Demonstrate greater confidence in their ability to [list][item]Work effectively in the multidisciplinary team to optimize the management of [italic]NTRK[/italic] fusion-positive cancer[/list]

Goal Statement

The goal of this activity is for learners to be better able to optimize treatment strategies for patients with [italic]NTRK[/italic] fusion-positive cancer.

Target Audience

This educational activity is intended for an international audience of oncologists, pathologists, pulmonologists, pediatricians, and endocrinologists.

Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.

Supported by an independent educational grant from Bayer.